Bank of New York Mellon Corp Acquires New Shares in Alimera Sciences, Inc. (NASDAQ:ALIM)

Bank of New York Mellon Corp bought a new position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 61,907 shares of the biopharmaceutical company’s stock, valued at approximately $344,000. Bank of New York Mellon Corp owned about 0.12% of Alimera Sciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALIM. Vanguard Group Inc. grew its holdings in shares of Alimera Sciences by 61.1% during the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the period. Ancora Advisors LLC purchased a new position in Alimera Sciences during the first quarter worth about $915,000. Deltec Asset Management LLC acquired a new stake in shares of Alimera Sciences during the second quarter valued at about $690,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Alimera Sciences in the 1st quarter valued at approximately $169,000. Finally, Fifth Lane Capital LP acquired a new position in shares of Alimera Sciences in the 1st quarter worth approximately $83,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALIM. HC Wainwright downgraded shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, StockNews.com began coverage on Alimera Sciences in a report on Sunday. They set a “hold” rating for the company.

Alimera Sciences Stock Performance

Shares of ALIM stock opened at $5.54 on Thursday. The firm has a 50 day moving average of $5.55 and a two-hundred day moving average of $4.47. The stock has a market capitalization of $290.24 million, a PE ratio of -3.53 and a beta of 1.25. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. Alimera Sciences, Inc. has a 52 week low of $2.61 and a 52 week high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The company had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. On average, research analysts predict that Alimera Sciences, Inc. will post -0.13 EPS for the current fiscal year.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).